Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

Phase 4

Completed

• Conditions: Type 2 Diabetes Mellitus; Obesity

• Registration Number: NCT00522470
• Lead Sponsor: Baskent University

Brief Summary

We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2007-08-27
• Study First Submitted QC: 2007-08-27
• Study First Posted: 2007-08-29
• Status Verified: 2008-05
• Last Update Submitted: 2008-05-07
• Last Update Posted: 2008-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

• newly diagnosed, drug naive women with type 2 diabetes

Exclusion Criteria

• presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke)
• presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Baskent University Hospital Department of Endocrinology; 🇹🇷 Ankara, Bahçelievler, Turkey